Why the study?
Cardiovascular outcome trials of newer antidiabetes drugs included only a small proportion of patients with baseline heart failure, limiting the available evidence on heart failure outcomes.
Do antidiabetes agents (SGLT-2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors) reduce cardiovascular risk and heart failure hospitalization in patients with type 2 diabetes mellitus?
Do antidiabetes agents (SGLT-2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors) reduce cardiovascular risk and heart failure hospitalization in patients with type 2 diabetes mellitus?
While SGLT-2 inhibitors and GLP-1 receptor agonists show significant cardiovascular benefits in T2DM, ongoing dedicated trials in heart failure populations are needed to broaden their use beyond conventional diabetes management.
Type 2 diabetes mellitus (T2DM) is a recognised risk factor for several cardiovascular (CV) conditions including heart failure (HF). Findings that reflect CV risk associated with T2DM medications have led to regulatory requirement of conducting CV outcome trials (CVOTs) for new antidiabetes drugs. Over the years, several CVOTs using different glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors have reported neutral or improved CV risks or hospitalisation for HF. However, these studies included only a small proportion of the patients with baseline HF thus limiting the available evidence. Ongoing trials such as EMPEROR programme and DAPA-HF in large patient populations with chronic HF could potentially broaden the use of these drugs beyond their conventional therapeutic indication.
No takes yet. Share an insight, caveat, or question.
Stefan D. Anker (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: